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Clinical trialThroughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-
morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a
major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear associa-
tion between obesity, low-grade inﬂammation and obesity-associated diseases, thus, the development of new
anti-inﬂammatory substances is urgently needed as these may ultimately pave the way for novel treatments of
obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in
the present review, we provide an overview of the ﬁeld, and discuss the future scientiﬁc perspectives. This article
is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical ﬁndings to improved patient
outcomes.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Throughout theWestern world obesity is a rapidly increasing prob-
lem gradually reaching epidemic heights [1]. Associated co-morbidities
such as type 2 diabetes are projected to rise steadily during the years to
come [161]. On the individual as well as on a societal level this detri-
mental condition comprises a major problem, as it predisposes to in-
creased overall morbidity and mortality [121,129].
The strong correlation between increasing adiposity and develop-
ment of obesity-associated diseases is well-established [45]; conse-
quently, the risk of death from various metabolic conditions
comprising the metabolic syndrome increases dramatically with in-
creasing fat mass, especially with increases in abdominal obesity [121,
134,169,171]. Despite these clear-cut correlations, the pathophysiologi-
cal background is not fully elucidated or agreed on. During the last de-
cades, it has, however, become clear that the adipose tissue itself
generates a systemic inﬂammatory process [75,99]. Traditional inﬂam-
matory responses are often transient and represent the organism's re-
sponse to potential harmful stimuli and as such constitute a favorable
homeostatic response. In general, however, prolonged inﬂammatoryatrol: Challenges in translating
l, Department of Endocrinology
0 Aarhus, Denmark. Tel.: +45reactions are often deleterious. This seems to be the case in obesity-
induced inﬂammation, which is considered a chronic metabolic low-
grade inﬂammatory state sometimes referred to as “metaﬂammation”
[75]. Following the general perception of the adipose tissue as a pas-
sive storage organ, it is todaywell-established that adipose tissue is a
complex endocrine organ playing a pivotal role in metabolic homeo-
stasis and immune regulation (Fig. 1). Some of the secreted factors,
termed adipokines, are exclusively synthesized by and secreted
from adipocytes, whereas numerous other unspeciﬁc cytokines, the
adipocytokines, are also secreted from various other cell types with-
in the adipose tissue.
For several reasons, great effort has in the recent years been put into
discontinuing the progression of the obesity epidemic and the associat-
ed low-grade inﬂammation. However, so far none of the available
strategies have managed to sufﬁciently curb the development. Conse-
quently, as the conventional preventive and therapeutic options seem
inadequate, physicians are instead obliged to resort to medical treat-
ment of the obesity-associated conditions and complications, often at
an advanced stage of the diseases.
As weight loss and weight maintenance remains a major problem,
new strategies to protect against obesity-related morbidity are needed.
There is a clear association between obesity, low-grade inﬂammation
and obesity-associated diseases, thus, the development of new anti-
inﬂammatory substances is urgently needed as these may ultimately
pave the way for novel treatments of obesity and lifestyle-related dis-
eases. A candidate molecule is the polyphenolic compound, resveratrol,
which is already widely distributed as an over-the-counter nutritional
Fig. 1. Inﬂammation and chronic diseases. Inactivity and obesity trigger persistent, low-grade systemic inﬂammation. Moreover, inﬂammation in certain tissues is linked to the develop-
ment of many chronic diseases. Examples of such tissues and the consequences of inﬂammation are shown. Inﬂammatory cytokines released from adipose tissue are linked to the devel-
opment of insulin resistance and type 2 diabetes. Inﬂammatory responses by immune cells and glial cells are associatedwith atherosclerosis, inﬂammatory bowel disease, arthritis, asthma
and neurodegenerative diseases, respectively. The systemic and local production of cytokines contribute to the etiology of certain cancers.
Adapted with permission from Nature (Spigelmann et al., vol 454, 463–469, 2008).
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human health.
2. Resveratrol
During the last decades, resveratrol has gained steadily increased at-
tention in relation to metabolic health. Resveratrol (3,5,4′-trihydroxy-
trans-stilbene) is a small polyphenolic compound chemically belongingto the stilbenoid class, and in the lay press, resveratrol is probably best
known as a constituent of grapes and wine, albeit in minute amounts
(in red wine on average 1.9 mg/L [139]). Triggered by this relation, in
the early 1990's resveratrol gained great attention as the ‘missing link’
to explain ‘the French paradox’ [36,125], which is the epidemiological
observation that French people appear to have relatively low incidence
of cardiovascular disease, despite consuming a diet high on saturated
fat. Even though this concept has scientiﬁcally been challenged since
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milestone appeared in 2006, as the Sinclair group demonstrated a
resveratrol-mediated shift in the physiology of middle-aged mice kept
on a high-calorie diet toward that of mice fed a standard diet, thereby
signiﬁcantly increasing their survival [11]. The ﬁrst randomized clinical
trial systematically examining metabolic effects in human subjects was
published in late 2011 [142].
An exhaustive description of the purportedmolecular-biological tar-
gets and overall physiological effects of resveratrol action is beyond the
scope of the present review, but one of the central elements in the ac-
tion of resveratrol is the anti-inﬂammatory potential, which per se
probably interconnects or directly affects other physiological outcomes,
e.g. diabetes, cancer, cardiovascular disease and neurodegeneration.
3. The inﬂammatory cascade
Low grade inﬂammation is observed in various other tissues than
the adipose tissue which is probably caused by different stimuli in spe-
ciﬁc cells within these tissues. The toll-like receptors (TLRs) belong to
the transmembrane pattern recognition receptors (PRRs) which are
key components of the innate immune system. They initiate a defense
response when pathogen-associated molecular patterns (PAMPs),
which derivate from cellular stress or microbial pathogens, or
damage-associated molecular patterns (DAMPs), which derivate from
cellular damage, bind to the speciﬁc PRRs. Endogenous compounds
such as saturated fatty acidsmay also bind to the PRRs and trigger an in-
ﬂammatory response [167]. Macrophages as well as adipocytes express
TLRs and it has been suggested that the TLRs may have an important
role in relation to the obesity-induced chronic low-grade inﬂammation.
Particularly, the expression of TLR4 and TLR2 is elevated in obesity and
metabolic diseases [4]. TLR4 binds LPS, an endotoxin which is found in
the outer membrane of gram-negative bacteria, and activates the tran-
scription factor NF-κBwhich triggers an inﬂammatory response. Certain
endogenous free fatty acids can also activate TLR4 and induce a similar
inﬂammatory response [100]. Moreover, high fat diet has been sug-
gested to increase the intestinal permeability for LPS and thereby trigger
the low-grade inﬂammation [25]. TLR2 binds lipoproteins from gram-
positive bacteria; however, it also recognizes viral, fungal, and endoge-
nous substances, which activate the NF-κB pathways. The activation of
the TLRs triggers a downstream signaling pathway which consists of
multiple paths. A family of IκB kinases (IKK) plays a central role in con-
trolling the NF-κB activity. The IKK control the signaling of NF-κB by
phosphorylating an inhibitor of NF-κB (IκBα), thus IκBα, sequesters
NF-κB in the cytosol. Upon TLR activation the IKK is activated and cata-
lyzes the phosphorylation of IκBα which releases NF-κB that translo-
cates into the nucleus and up-regulates genes associated with
inﬂammation e.g. IL-6, MCP-1, and TNF-α [67]. The c-Jun amino-
terminal kinases (JNKs) are also activated by inﬂammatory cytokines
and free fatty acids and increased JNK activity is associated with low-
grade inﬂammation and insulin resistance [73] (Fig. 2).
A recent study by Ahmad et al. demonstrated an increased expres-
sion of both gene and protein levels of TLR2 and TLR4 in the subcutane-
ous adipose tissue and monocytes from obese subjects compared with
lean subjects [4]. Accordingly, the TLRs may be important targets for
therapeutic approaches reducing obesity and low-grade inﬂammation.
4. Low-grade inﬂammation in obesity
The ﬁrst clear indication connecting obesity, low-grade inﬂamma-
tion, and development of obesity-related morbidity was the ﬁnding
that TNF-α overexpression in adipose tissue of obese rodents contribut-
ed to insulin resistance [77]. This association was supported by studies
demonstrating improved insulin sensitivity and glucose homeostasis
in obesemice lacking the TNF-α function [150,151]. These pioneer stud-
ies were consolidated by similar ﬁndings in humans [76,86,93,138].
Taken together, the studies on TNF-α conﬁrm that the inﬂammatoryresponse induced by adiposity is critically involved in the insulin action
in obesity.
It is today clear that an array of other adipocytokines/chemokines
than TNFα is also increased in obesity, e.g. IL-6, IL-8, and MCP-1. More
or less potent, thesemediators in variousways contribute to the inﬂam-
matory state of obesity and the overall link connecting obesity and the
inﬂammatory networks has recently been strengthened in a study
using large scale genetic transcription analysis [49].
In order to develop novel therapeutically modalities it is important
to understand how the obesity-induced low-grade inﬂammatory pro-
cess is initiated and maintained. This is important since obesity is nei-
ther a necessity nor prerequisite for developing metabolic disease. In
fact, up to 30% of the obese individuals appear metabolically healthy
[83]. Conversely, in the general population the prevalence of normal
weight individuals displaying a cluster of obesity-related abnormalities
is approximately 20% [85]. Furthermore, no standardized criteria to cat-
egorize metabolically healthy but obese individuals exist. However,
some characteristics recur such as a favorable lipid proﬁle and low vis-
ceral fat content [83]. Based on a previous cohort study, it can be sug-
gested that the inﬂammatory proﬁle is a predictor of morbidity in
obesity [84], and consequently it is important to study the biological
mechanisms of low-grade inﬂammation.
Despite a positive correlation between the degree of obesity and the
level of circulating of pro-inﬂammatory cytokines/chemokines like TNF-
a, IL-6, MCP-1, IL-8, and acute phase reactants like C-reactive protein
(CRP) [32,64,87,152,154] the increase in the absolute levels of theseme-
diators is often only modestly elevated about 2-fold compared with the
level in non-obese subjects [9,51]. The degree of low-grade inﬂamma-
tion is not only associated with the body weight but also an unhealthy fat
distribution has a profound effect on the inﬂammatory status [85,92],
thus, abdominal and especially visceral fat accumulation is associated
with increased level of pro-inﬂammatory cytokines/chemokines [70,71].
Adiponectin and leptin, which are two adipokines, exclusively se-
creted by the adipocytes, have attracted great attention since both
adipokines constitute central elements in appetite regulation, energy
balance, and innate immunity [141]. Large population studies have
shown that the concentration of adiponectin and leptin strongly corre-
lates with the risk of diabetes and cardiovascular disease [78,104]. The
level of adiponectin correlates inversely with BMI [141] and the
obesity-associated decrease in adiponectin is, based on pre-clinical ex-
perience, considered a causal pathophysiological factor [3]. Overexpres-
sion of adiponectin in mice has a protective function by reducing the
formation of atheromatous plaques and reducing the infarct size after
myocardial infarction [116]. Conversely, high levels of IL-8 and MCP-1
are thought to be important for the development of atherosclerosis
[42,43]. Furthermore, it is shown that the metabolic disturbances ob-
served in lipo-atrophic transgenic mice can be rescued by treatment
with leptin and adiponectin [163,164]. Thus, the low adiponectin
level, which is seen in obese individuals, is suggested to cause insulin re-
sistance, higher degree of inﬂammation, and to have negative effects on
cardiovascular health.
The obesity-induced inﬂammation (metaﬂammation) is reﬂected in
the adipose tissue by an overexpression of the inﬂammatory genes in-
cluding MCP-1, PLAUR, CSF-3, and HIF-1alpha [7,21]. Furthermore, an
increased number of macrophages inﬁltrate the adipose tissue in rela-
tion to chronic low-grade inﬂammation in obesity [39,159]. The fat dis-
tribution plays an important role in relation to the inﬂammatory state,
thus, the visceral adipose tissue contains a higher number of macro-
phages than the subcutaneous adipose tissue [19,22,71] and accordingly
have a higher degree of local inﬂammation. Traditionally, macrophage
phenotypes are divided into pro-inﬂammatory (M1) and anti-
inﬂammatory (M2) subpopulations. M1 or classical activated macro-
phages are induced by substances like LPS and TNFα and produce pro-
inﬂammatory cytokines whereas M2 or alternative activated macro-
phages are induced by substances like glucocorticoids, adiponectin
and Il-10 to produce anti-inﬂammatory cytokines [40].
Fig. 2. Potential cellular mechanisms for activating inﬂammatory signaling. Obesity and high-fat diet activate IKKβ/NF-κB and JNK pathways in adipocytes, hepatocytes, and associated
macrophages. Stimuli that have been shown to activate these pathways during metabolic dysregulation include ligands for TNF-α, IL-1, Toll, or AGE receptors (TNFR, IL-1R, TLR, or
RAGE, respectively), intracellular stresses including ROS and ER stress, ceramide, and various PKC isoforms. Obesity-induced IKKβ activation leads to NF-κB translocation and the increased
expression of numerousmarkers and potential mediators of inﬂammation that can cause insulin resistance. Obesity-induced JNK activation promotes the phosphorylation of IRS-1 at ser-
ine sites that negatively regulate normal signaling through the insulin receptor/IRS-1 axis. Examples include serine-302 (pS302) and serine-307 (pS307). By contrast, evidence has not
been reported for obesity-induced effects on transcription factors such as AP-1 that are regulated by JNK. IKKβ and/or NF-κB are inhibited or repressed by the actions of salicylates,
TZDs, and statins.
Reprinted with permission from Journal of Clinical Investigation (Shoelson et al., 116(7):1793–801, Jul 2006).
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crown-like-structures (CLSs) surrounding dead or dying adipocytes
and it has been suggested that theymay have a scavenger function in re-
sponse to the necrotic adipocytes [33]. The presence of CLSs in the adi-
pose tissue is a strong indicator of local inﬂammation in the adipose
tissue [160] (Fig. 3). The accumulating adipose tissue macrophages
produce several pro-inﬂammatory cytokines and are suggested to be
major contributors to the systemic low-grade inﬂammation. Recently,
it was shown that the number of macrophages in human adipose tissue
was increased in relation to obesity in subcutaneous adipose tissue and
the expression of pro-inﬂammatory cytokines was elevated in adipose
tissue from obese subjects, but interestingly, when normalized for
the number of macrophages the expression proﬁle indicated that the
macrophages in obese subjects were changed toward a more anti-inﬂammatory proﬁle (M2 phenotype) [54]. Besides macrophages, also
the adipocytes play an important role in relation to the low-grade in-
ﬂammation by their production of adipokines. Increased expression
and secretion of adipokines are seen in relation to hypertrophic adipo-
cytes [135], which occur due to excess fat accumulation in the adipose
tissue. The fat depots differ in the production of adipokines and
chemokines as the subcutaneous adipocytes have a higher production
of leptin and adiponectin compared with the visceral adipocytes [68,
149], and the visceral adipocytes have a higher production of e.g. IL-8,
IL-6, and MCP-1 than the subcutaneous adipocytes [18,19,52].
Accumulation of lipid in the subcutaneous adipose depot corre-
sponding to the gluteal and femoral area, is not associatedwith negative
health consequences whereas accumulation of adipose tissue in the ab-
dominal adipose depot and especially in the visceral adipose depot is
Fig. 3. CD68-positive macrophages arranged in crown-like structures in visceral adipose
tissue from an obese subject (20×). Photo: Fjeldborg K.
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betes [79]. It has been proposed that the adipose tissue has a deﬁned in-
dividual capacity to expand and when this limit is exceeded the lipid
will deposit ectopically in non-adipose tissues such as the liver, skeletal
muscles, pancreas, and other organs in which it causes local inﬂamma-
tion and other toxic effects [153].
Several hypothetical links between obesity and low-grade in-
ﬂammation exist. Prevailing hypotheses on how obesity-induced
low-grade inﬂammation is initiated include macrophage inﬁltration,
adipocyte hypertrophy, adipocyte cell death, nutrient-induced im-
mune responses, endoplasmatic reticulum stress, oxidative stress,
toll-like receptor activation, gut microbiota, and adipose tissue hyp-
oxia [67,140,147,165].
Accumulation of excess lipid in the adipose tissue leads to adipocyte
hypertrophy which may exceed the diffusion distance of oxygen and
cause local hypoxia in the adipose tissue. The local hypoxia is conse-
quently suggested to induce inﬂammation and increase the number of
macrophages in the adipose tissue [147]. However, adipose tissue
hyperoxia as a result of reduced oxygen extraction and mitochondrial
dysfunction in the adipocytes has also been suggested to be associated
with low-grade inﬂammation in obese subjects [65]. This theory is sup-
ported by the fact thatmost experimental studies on adipose tissuehyp-
oxia have been performed under very low PO2 levels (for normoxia,
cells are incubated in the presence of the 21% O2, whereas for hypoxia,
1–2% O2 is generally used [146]) which may not reﬂect the physiology
of the human adipose tissue. Another theory behind the low-grade in-
ﬂammation is that the adipocyte hypertrophy leads to adipocyte necro-
sis. The necrotic adipocytes release cellular components which lead to
an inﬂammatory responsewith activation of themacrophages that inﬁl-
trate the adipose tissue and aggregate around the necrotic adipocytes
forming crown-like structures (CLS) [33]. Excess lipid accumulation
andmechanical stress in relation to obesity are linked to endoplasmatic
reticulum (ER) stress which is associated with activation of the inﬂam-
matory pathways [66,117].When ER is challengedwith excess nutrients
the unfolded protein response (UPR) is activated. This process subse-
quently links to major inﬂammatory pathways, including the activation
of JNK-AP-1 and IKB kinase nuclear factor κB (IKK-NFκB) [66]. Accumu-
lation of excess lipid has also increased the systemic oxidative stress,
thus, the elevated level of reactive oxygen speciesmay lead to a dysreg-
ulated production of adipokines in the adipose tissue [57]. Elevated
levels of free fatty acids released from the enlarged adipose tissue in
obese subjects may induce inﬂammatory signaling by stimulating the
toll-like receptors present on immune cells and adipocytes. Also nutri-
tional free fatty acids can activate the toll-like receptors [133].Furthermore, it has been suggested that a diet high on fat may change
the gutmicrobiota and increase the intestinal permeability for lipopoly-
saccharides (LPS) [25] leading to higher circulating LPS levels which
may induce inﬂammation via direct stimulation of the toll-like receptor
in adipocytes, immune cells, and other important cells like the hepatic
cells [58]. Based on animal studies the chronically increased plasma
levels of LPS, termed metabolic endotoxemia, seem causally associated
with obesity, insulin resistance and diabetes, as endotoxemia induced
by continuous subcutaneous LPS infusion induces similar metabolic de-
rangements as high fat diet. Consequently it is speculated that lowering
plasma LPS concentrations could provide a novel approach in
preventing metabolic diseases [24]. Finally, physical inactivity has also
been associated with increased low-grade inﬂammation as seen by an
increase in the level of hs-CRP [98]. Themechanisms behind this associ-
ation are not completely settled but changes in the adipose tissue vol-
ume might be of importance. Moreover, a direct effect of physical
activity has been proposed. Physical activity is known to activate
AMPK which subsequently may regulate the inﬂammatory cascade via
stimulation of PGC-1α and inhibition of NF-kB [113].
There are several mechanisms that may induce low-grade inﬂam-
mation in relation to obesity; however, the precise underlying patho-
physiological mechanism is not elucidated. The increased numbers of
immune cellswithin the adipose tissue play an essential role andweight
loss intervention studies have demonstrated a reduction in the number
of adipose tissue macrophages and in the level of circulating pro-
inﬂammatory cytokines in relation to weight loss [10,17,21,31,53,69]
indicating that the inﬂammatory process is dynamically regulated and
may therefore be a potential target for intervention.
As weight loss regimens tend to fail, various approaches have been
explored in order to circumvent the low-grade inﬂammation associated
with obesity. In addition to resveratrol and similar compounds (eg.
Salsalate and Aspirin, see later) the intimate relation between gut mi-
crobiota alterations in relation to weight changes and metabolic mor-
bidity serves as another ﬁeld of future interest: In a recently published
review it is suggested that modulation of intestinal permeability
through interventions that modify the composition of the intestinal mi-
crobiota, or activation of the immune system and associated inﬂamma-
tory responses, may constitute a key strategy to address obesity and
obesity-related disease [34]. Another approach is modulation of the
inﬂammasome by affecting central inﬂammatory mediators: By means
of an IL-1 receptor antagonist or IL-1β antagonism systemic markers
of inﬂammation are decreased and pertinent physiological markers of
glucose homeostasis are improved [26,96,97,127,136]. As stated earlier
TNFα seems crucially involved in low grade inﬂammation and develop-
ment of insulin resistance, however, the effect of TNFα antagonists on
insulin resistance in patients with metabolic syndrome or diabetes is
only detected in some [138] but not all studies [46,114,119]. On the
other hand insulin sensitivity was improved in non-diabetic patients
with rheumatoid polyarthritis [90]. Other pharmaceutical targets
being currently explored include IL6 antagonists, AMPK activators
other than Metformin, mTOR inhibitors, CCR-2 antagonists and, ﬁnally,
SIRT1 activators other than resveratrol [50].
5. Consequences of low-grade inﬂammation
The obesity-associated low-grade inﬂammation has been suggested
to be the culprit for many serious diseases and conditions affecting mil-
lions of people throughout the world. Especially, the so-called lifestyle
diseases have been related to low-grade inﬂammation which includes
the development of insulin resistance, type 2 diabetes, cardiovascular
disease, certain cancers, and neurodegenerative diseases [27,41,102,
137] (Fig. 1). The elevated levels of circulating pro-inﬂammatory cyto-
kines characterizing low-grade inﬂammation have been suggested to
induce insulin resistance e.g. by inducing phosphorylation of serine res-
idues of the insulin receptor substrate-1 (IRS-1) which impairs the nor-
mal insulin signaling pathway. Also high levels of free fatty acids can
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dues of IRS-1 [133].
The association between low-grade inﬂammation and metabolic
consequences could be either a coincidence or causative. The causative
link, in relation to insulin resistance, was established by a proof-of-
concept study performed by Fleischman et al. which proved that
treating young obese and insulin resistant subjects with the anti-
inﬂammatory drug, Salsalate (prodrug of salicylate), not only improved
the inﬂammatory state but also improved various metabolic variables
including the insulin sensitivity and HbA1c [55]. Subsequently these
ﬁndings were corroborated in a larger multicenter study (the TINSAL-
T2D trial) [62] in which it was shown that Salsalate treatment reduced
inﬂammatory mediators and improved glycemic control in patients
with T2DM. Likewise, treating obese and insulin resistant rodents with
the anti-inﬂammatory compound Aspirin demonstrated that inhibition
of the inﬂammatory kinase IKKβ by Aspirin resulted in improved insulin
sensitivity, andmoreover, reduced triglyceride and free fatty acid levels
[168] Salsalate and Aspirin are chemically related as both are built on
salicylic acidwhich is originally a plant derived phenolic phytohormone
which is produced by plants in response to pathogens. Also resveratrol
is a phenolic phytohormone which is produced by plants in response
to stress (Fig. 4).
Finally, targeting ER stress [118] and PPARγ [72] have demonstrated
anti-inﬂammatory effects and beneﬁcial outcomes onmetabolic distur-
bances. Accordingly, some evidence exists that resveratrol in animal
models, reduces ER stress [103] and induces PPARγ [56,156], hereby
yielding beneﬁcial effects in relation to retinal ER stress and atherogen-
esis, respectively.
Taken as a whole, modulation of the inﬂammatory status associated
with obesitymay likely affect metabolic variables in a positive way, and
once again this underscores the need for novel therapeutic approaches.
6. Anti-inﬂammatory effects of resveratrol in vitro
Several biological targets of resveratrol have been reported, how-
ever the mechanisms by which resveratrol exerts its biological func-
tions are still not fully elucidated (Fig. 5). Resveratrol exhibits its anti-
inﬂammatory effects through various pathways that lower the NF-κB
activity. Resveratrol inhibits the activity of especially cyclooxygenase-1
(COX1) [23] and the expression of COX1 and COX2, which are rate limit-
ing enzymes involved in the production of pro-inﬂammatory mediators
[6]. Moreover, the activity of microsomal prostaglandin E synthase-1
(mPGES-1), which is an essential enzyme responsible for the synthesis
of the pro-inﬂammatory prostaglandin E2 (PGE2), has also been shown
to be attenuated by resveratrol [23].Fig. 4. Chemical structure of resveratrol, salicylate, salsalate and aspirin.Hypoxia is a strong inducer of inﬂammation in the adipose tissue
in vitro [146], and interestingly resveratrol attenuates the hypoxia
induced inﬂammation in human adipose tissue explants [38]. A
recent preclinical study has demonstrated that hypoxia-inducible
factor 2α (HIF-2α) attenuates adipose tissue inﬂammation [29],
thus, resveratrol may have an indirect anti-inﬂammatory effect
since it is shown that SIRT1 is an inducer of HIF-2α in relation to
hypoxia [44].
After binding of LPS to the toll like receptor (TLR) the cells respond
by increasing the production of inﬂammatory cytokines which are
inhibited by resveratrol. The study by Kim et al. dissected the involved
pathways and reported that resveratrol suppressed the adaptor protein
Toll Receptor-domain-containing-adaptor-inducing interferon-beta
(TRIF) and the TANK-binding kinase (TBK) which resulted in lower ac-
tivation of NF-kappaB, interferon regulatory factor 3 (IRF3) and activa-
tor protein 1 (AP-1) [89].
Another possible anti-inﬂammatory pathway utilized by resveratrol
could be through the estrogen receptor. Estradiol possesses anti-
inﬂammatory effects via estrogen receptor-alpha by controlling the in-
tracellular localization of NF-kappaB [60] and resveratrol acts as a
mixed agonist/antagonist for estrogen receptors [15]. However, at
least in human adipose tissue fragments the anti-inﬂammatory effects
of resveratrol are not mediated via estrogen receptors as an estrogen
receptor-blocker did not affect the resveratrol effect [115].
Recently, death-associated protein kinase1 (DAPK1) has been
proposed as a modulator of inﬂammation [111,112]. DAPK1 inhibits
NF-kB activation and pro-inﬂammatory cytokine expression after
stimulation with LPS and TNFa: however, other studies have report-
ed a pro-inﬂammatory effect of DAPK1. The difference in pro- or
anti-inﬂammatory effects of DAPK1 could be cell type dependent
and/or depend upon the intra-cellular protein pool available as
DAPK1 interacts via protein–protein binding; reviewed in [94]. This
is interesting as resveratrol has increased the expression level of DAPK1
in human ﬁbroblasts [30] raising the possibility that at least some of the
anti-inﬂammatory effects of resveratrol might be caused by the regula-
tion of DAPK1 which subsequently regulates the inﬂammatory status.
Numerous in vitro studies support the notion that resveratrol has
strong anti-inﬂammatory effects in a variety of cell models, and the
anti-inﬂammatory effect seems unrelated to the inﬂammatory stimulus.
Thus, resveratrol attenuates inﬂammation and suppresses the activa-
tion of NF-κB in cells stimulated with e.g. LPS, TNF-α, or other well-
known activators of inﬂammation [108,148]. The anti-inﬂammatory ef-
fects of resveratrol have been described in macrophages [148], T3T
preadipocytes [172], endothelial cells [37], smooth muscle cells [91],
chondrocytes [132],microglial cells [23], and adipose tissue [115]. Final-
ly, in human adipocytes incubated with resveratrol, secretome analysis
has indicated a less inﬂammatory phenotype resembling the outcome
of calorie restricted adipocytes [126].
7. Anti-inﬂammatory effects of resveratrol in animal studies
Several animal studies have substantiated the anti-inﬂammatory ef-
fects of resveratrol found in vitro, and conﬁrmed some of the proposed
mechanisms of action. Among studies thoroughly exploring anti-
inﬂammatory potential, Wang B. et al. fed C57BL/6 mice a high fat diet
(HFD) and mice were designated as either diet-induced obese (DIO)
mice or diet-resistant (DR) mice. A control group was fed a standard
diet for comparison. DIO mice and DR mice were further subdivided
into three groups receiving HFD alone, HFD with 0.03% resveratrol, or
HFD with 0.06% resveratrol for 13 weeks. HFD alone increased TNF-α,
IL-1, and IL-6, and decreased IL-10 in DIO mice compared to control
mice. DIO mice supplemented with resveratrol exhibited decreased
TNF-α, IL-1, and IL-6, and increased IL-10 compared to DIO mice fed
HFD alone. The anti-inﬂammatory effects of resveratrol were dose-
dependent [158]. Rivera L. et al. investigated the effects of resveratrol
supplementation in obese Zucker rats. For eight weeks either vehicle
Fig. 5. Purported molecular biological targets of resveratrol in relation to anti-inﬂammatory and anti-oxidative processes.
1130 M.M. Poulsen et al. / Biochimica et Biophysica Acta 1852 (2015) 1124–1136or resveratrol (10mg/kg bodyweight daily) was administered orally by
gavage. Administration was stopped two days prior to termination of
the study, in order to identify long-term effects rather than acute effects
of resveratrol treatment. Resveratrol treatment increased adiponectin
and decreased TNF-α production from the visceral adipose tissue com-
pared to vehicle treatment. Additionally, resveratrol enhanced the eNOS
expression in the visceral adipose tissue and aorta, and resulted in an
improvement in the dyslipidemia, hyperinsulinemia, and hypertension
normally characterizing the obese Zucker rats. The authors suggested
that effects were mediated by AMPK activation [128]. Using SIRT1
knockout mice it was demonstrated that the activation of AMPK by res-
veratrol could be both mediated via SIRT1 dependent pathways (low
resveratrol dose) and via SIRT1-independent pathways (high resvera-
trol dose) [124]. Another study using Zucker rats conﬁrmed these
anti-inﬂammatory effects of resveratrol (15 mg/kg body weight daily).
Six weeks of resveratrol treatment reduced serum levels of TNF-α,
MCP-1, and CRP compared to control animals. The modulation of plas-
ma cytokine levels may result from decreased NF-κB activity and re-
duced macrophage inﬁltration in the adipose tissue [63]. Also, a study
in C57BL/6mice fed HFD for 20 weeks, found a reduction in adipose tis-
sue macrophage inﬁltration and serum TNF-α levels in response to
high-dose resveratrol treatment (200 mg/kg body weight daily) [80].
Likewise, in a model of colitis, resveratrol (10 mg/kg body weight
daily) prevented the expected increase in TNF-α and reduced the ex-
pected overexpression of COX-2, in addition to a signiﬁcant decrease
in NF-κB [109]. Finally, in 2013 Jimenez-Gomez Y. et al. published inter-
esting data from a quasi-randomized trial investigating the effects of
long-term resveratrol treatment in adult rhesus monkeys. Animals
were divided into three groups receiving high fat/high sugar diet
(HFS) + resveratrol, HFS + placebo, or standard diet. The dose of res-
veratrol was 40 mg twice daily the ﬁrst year, followed by 240 mg
twice daily for another year. Resveratrol has been proven to increase
the SIRT-1 expression, decrease the NF-κB activation, and decrease the
mRNA expression for IL-6, TNF-α, IL-1β, and adiponectin in the visceral
adipose tissue [81].
In addition, resveratrol has anti-inﬂammatory effects in a variety of
other rodent disease models. In an arthritis model induced by intra-
articular LPS injections showed that subsequent injection of resveratrol
in the affected knees reduced inﬂammation and preserved cartilage
[47]. Another model of arthritis revealed similar effects of resveratrolon protection of cartilage, whereas in this model resveratrol did not in-
hibit synovial inﬂammation [48]. In cell culture resveratrol also pos-
sesses positive effects on chondrocytes [88,106].
In amicemodel of inﬂammatory bowel disease induced by infection
with Toxoplasma gondii resveratrol could decrease inﬂammation and
improve survival [12], and similar ﬁndings have been presented in an-
other model using dextran sulfate sodium to induce colitis. In this
model resveratrol protected mucosa and reduced systemic inﬂamma-
tion [95].
In the asthmatic mouse model induced by ovalbumin sensitization
of resveratrol reduced inﬂammatory response, mucus hypersecretion
and airway hyperresponsiveness [101], and in another study using the
samemodel resveratrol similarly reduced inﬂammation and also airway
remodeling [130].
From these animal studies it seems reasonable to conclude that
resveratrol in the majority of models holds the potential to modulate
inﬂammatory pathways. The effects are quite consistent across animal
species, across wide dosing ranges, and across various treatment
durations. Suggested mechanisms primarily evolve around decreased
NF-κB activation and possibly reduced macrophage inﬁltration in the
adipose tissue. SIRT-1, AMPK, and eNOS are other possible mediators.
Nonetheless, anti-inﬂammatory action is not an essential prerequisite
for mediating physiological effects of resveratrol [122].
8. Anti-inﬂammatory effects of resveratrol in human clinical trials
Based on in vitro studies and animal models the pre-clinical evi-
dence demonstrating anti-inﬂammatory effects of resveratrol via Sirt1
activation is substantial. It has been demonstrated that human tissues
(muscle [105] and adipose tissue [120]) express Sirt1 and that the ex-
pression is regulated similarly to what have been demonstrated in ro-
dents. On this basis clinical studies on effects of resveratrol in humans
were initiated, however, demonstration of a clinical relevant anti-
inﬂammatory effect of resveratrol has been more challenging than an-
ticipated and most positive ﬁndings remain modest, yet signiﬁcant.
Thus, the clinical results are not as promising as the pre-clinical data.
A small number of long-term intervention studies have demonstrated
modest reductions in the degree of inﬂammatory parameters based on
direct measurement of the plasma levels of well-known pro-
inﬂammatory markers [14,142–144] (see Table 1 for a complete list).
Table 1
Human clinical trials investigating anti-inﬂammatory potential of resveratrol. Arranged alphabetically. White background denotes anti-inﬂammatory and/or anti-oxidant effect, gray
denotes absence of anti-inﬂammatory effect. White/gray does not differentiate between potential physiological effects [8,13,16,35,107,162,170].
Study Design Outcome
Agarwal et al. [2] Double–blind randomized study.
400 mg resveratrol vs. placebo daily for 30 
days.
N = 44 healthy subjects.
Significantly reduction in plasma level of IFNγ.
No change in TNFα, IL–6 or leptin.
Improved fasting insulin.
Bakker et al. [8] Double–blinded, placebo–controlled cross–
over.
Dietary mix containing resveratrol
N = 36 healthy overweight men.
Modulation of inflammation and oxidative and  
metabolic stress
Bhatt et al. [13] Randomized study.
250 mg resveratrol vs. no resveratrol daily  
for 3 months.
N = 62 type 2 diabetic patients.
Anti–inflammatory effect not examined.
(Improved HbA1c)
Bo et al. [14] Randomized, double–blinded, cross–over 
study
500 mg resveratrol vs. placebo for 30 days
N = 50 healthy adult smokers
Decrease in CRP and Total Antioxidant Status
(TAS)
Brasnyo et al. [16] Double–blind study.
5 mg x 2 resveratrol vs. placebo daily for 4 
weeks..
N = 19 type 2 diabetic patients
Decreased oxidative stress. 
(Improved insulin sensitivity)
Chachay et al. [28] Randomized, double–blinded, placebo–
controlled.
3000 mg resveratrol vs placebo for 8 weeks.
N = 20 overweight or obese men with 
NAFLD.
No anti–inflammatory or metabolic effects.
Crandall et al. [35] Open–label study.
1, 1.5, or 2 g resveratrol daily for 4 weeks.
N = 10 subjects with impaired glucose 
tolerance.
No change in hs–CRP or adiponectin.
(improved postprandial glycemia)
Ghanim et al. [59] Randomized study.
40 mg resveratrol  vs. placebo daily for 6 
weeks.
N = 20 lean and healthy subjects.
Significantly decreased plasma level of TNF–α and 
CRP.
Suppression of ROS generation.
Suppressed intranuclear binding of NFκB, TNFα 
and IL–6 in isolated mononuclear cells.
Gliemann et al. [61] Randomized, double–blinded, placebo–
controlled.
250 mg resveratrol vs. placebo. Both groups 
with concomitant high intensity exercise 
training.
N = 27 inactive men.
Resveratrol blunts the positive effect of exercise 
training on cardiovascular health.
Magyar et al. [108] Double–blind study.
10 mg resveratrol vs. placebo daily for 3 
months.
N = 40 post–infarction subjects
No change in HbA1c, TNFα or CRP.
McAnulty et al. [111] Double–blinded cross–over study. IL–8 and CRP were unaffected by treatment (in 
Various resveratrol doses + quercetin vs. 
placebo.
N = 14.
relation to acute exercise induced stress).
Poulsen et al. [124] Double–blinded, randomized, placebo–
controlled study.
1.5 g resveratrol vs. placebo daily for 4 
weeks.
N = 24 obese subjects.
No change in hs–CRP, IL–6, TNF–α, leukocytes or 
MCP–1. 
(No change in HOMA–IR)
Semba et al. [132] Prospective cohort study.
N = 783 community–dwelling men and  
women 65 years or older.
Total urinary resveratrol metabolite 
concentration was not associated with 
inflammatory markers, cardiovascular disease, or 
cancer or predictive of all–cause mortality.
Timmers et al. [143] Double blind cross over study..
150 mg resveratrol vs. placebo daily for 30 
days. 
N = 11 obese subject
TNF–a, Leptin, leukocytes significantly decreased.
Tendency towards a reduction in CRP and IL–6. No 
change in adiponectin and IL–8.
Improved HOMA–IR.
Microarray analysis.
Tome–Carneiro et al. [145] Triple–blind randomized study.
8 mg resveratrol vs. grape extract without 
resveratrol vs. placebo daily for 12 months. 
N = 75 male participants
Significantly increased plasma level of 
adiponectin, and decreased PAI–1.
(tendency towards decreased CRP, no change in 
TNFα or IL6)
Voduc et al. [156] Randomized, double–blinded cross–over 
study.
500–1000 mg resveratrol vs placebo for 4 
weeks.
N = 13 healthy sedentary adults.
Inflammatory parameters unaffected.
Witte et al. [163] Randomized study.
200 mg resveratrol vs. placebo daily for 26 
weeks.
N = 26 overweight subjects.
Significantly reduction in TNF–α and IL–6 both in 
resveratrol and placebo group.
(Improved HbA1c)
Yoshino et al. [167] Double blind randomized study.
75 mg resveratrol vs placebo daily for 12 
weeks.
N = 29 non–obese subjects.
No change in leptin, CRP, IL–6 or adiponectin. 
(no change in HOMA–IR)
Zahedi et al. [171] Randomized study.
40 mg resveratrol vs. placebo daily for 6 
weeks.
N = 20 healthy, exercising subjects.
Significantly decreased levels of TNF–α and IL–6.
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and anti-inﬂammatory effects in human subjects was published in late
2011 by Timmers et al. [142]. In this placebo controlled, double blinded
cross over study 11 obese but otherwise healthymale participantswere
treatedwith resveratrol and placebo for fourweeks with an intervening
wash out period. Signiﬁcant albeit moderate improvements were re-
corded in various metabolic parameters like HOMA-IR index, lipid pro-
ﬁle and in the context of the present review a small reduction in TNFα
and a tendency toward lower IL6 level. Other studies have revealed
anti-inﬂammatory potential based on genetic expression of cytokines
obtained from white blood cells [145].
However, the topic is highly complex as an additional number of
randomized clinical trials fail to demonstrate any anti-inﬂammatory ef-
fect of resveratrol [28,123,131,166] (see Table 1 for a complete list). In
the work by Yoshino et al., published in October 2012, 29 non-obese
postmenopausal womenwere treatedwith resveratrol (N=15) or pla-
cebo (N = 14) for 12 weeks [166]. Exhaustive metabolic examination
did not reveal any physiological effect nor anti-inﬂammatory potential.
This corresponds with the outcome of our own clinical, randomized,
placebo controlled, parallel group trial in which 24 obese but otherwise
healthy male participants were randomized to resveratrol (N = 12) or
placebo treatment for fourweeks [123]. It should be kept inmind, how-
ever, that none of the studies referenced above have explicitly been de-
signed to evaluate the anti-inﬂammatory potential as the primary
outcome.
In a study by Agarwal et al. [2] therewas no signiﬁcant change in the
degree of inﬂammationmeasured in plasma, however, plasma from the
resveratrol treated subjects had a signiﬁcant anti-inﬂammatory effect
on human coronary artery endothelial cells.Microarray analysis on skel-
etal muscle biopsies has demonstrated that several genes related to in-
ﬂammation are down-regulated upon resveratrol supplementation
[142]. Finally, supplementation with 40 mg resveratrol pr. day for
6 weeks has shown to reduce the expression of TNF-α and IL-6, de-
crease the nuclear binding of NF-κB, and suppress the generation of
ROS in isolated mononuclear cells [59]. Taken as a whole, the majority
of clinical studies have been designed and conducted in order to evalu-
ate diverse metabolic outcomes, and as illustrated in Table 1, in both
groups of studies (yielding positive and negative outcomes), doses
and treatment duration vary considerably. This renders direct compari-
son nearly impossible and reviewing highly complex. However, among
the published studies, approximately half of the studies ﬁnd an anti-
inﬂammatory effect (and among these someﬁnd an improvement of in-
sulin sensitivity) whereas the other half of the studies ﬁnd no effect of
resveratrol in clinical trials (Table 1).
The acute effect of resveratrol on oxidative stress and inﬂammation
in response to intensively exercise has also been examined in a double-
blind randomized cross-over study [110]. The subjects were treated
with resveratrol (120mgdaily) or placebo for 6 days and on the seventh
day before exercise the subjectswere treatedwith double dosage of res-
veratrol (240 mg) or placebo. Resveratrol attenuated post-exercise in-
creases in oxidative stress, however, no difference in the plasma levels
of IL-8 or hs-CRP was found. In another study, resveratrol blunted the
positive effect of exercise training, but unfortunately no inﬂammatory
parameters were measured [61]. Finally, in a third exercise study, nei-
ther aerobic capacity nor inﬂammatory markers were affected by res-
veratrol treatment [155].
The differences between the results in the clinical trials may be at-
tributable to differences in the study populations. Gender, age, dosage
of resveratrol, length of the study, and the health status of the partici-
pants have been suggested to be factors inﬂuencing the results. Espe-
cially, a large difference has been found in the concentration and
dosage of resveratrol among the clinical studies. No consensus exists
on which concentration of resveratrol may be ideal in relation to anti-
inﬂammatory effects. Furthermore, when comparing in vitro studies
with human studies it has become clear that the concentrations of res-
veratrol used in in vitro studies are unattainable in human clinicalstudies. Based on human studies it has been shown that the absorption
of resveratrol is high, however the bioavailability is low since it is rapid-
ly metabolized [5,157]. Accordingly, it has been suggested that resvera-
trol may possess biological effects despite low plasma levels, partly
mediated by bioactive metabolites of resveratrol [20,74].
9. Future perspectives
Future studies on the anti-inﬂammatory effect of resveratrol in a
clinical setting should address the limitations mentioned above which
affect our present understanding of the effects. The studies should
have enough power to detect differences, pure high-quality resveratrol
should be used, a range of doses should be tried, long-term studies
should be designed (at least 4 month) and the participants should be
well characterized. Only by adhering to such strict methodology the
anti-inﬂammatory effect of resveratrol can be deﬁned in humans. In ad-
dition, more studies on the metabolism of resveratrol and the possible
effect of resveratrol metabolites need attention. In addition, the com-
bined effect of resveratrol and piperine needs further studies, as piper-
ine enhances the bioavailability of resveratrol probably by inhibiting
enzymes involved in the metabolism of resveratrol hereby increasing
the plasma level of resveratrol considerably [82]. However, in elevating
the plasma levels of resveratrol safety studies urgently need to focus on
potential side effects, and besides, it remains unknown whether or not
elevated plasma levels of resveratrol result inmore robust physiological
clinical outcomes.
10. Conclusion
As demonstrated above, at the pre-clinical level, the evidence of
resveratrol-mediated anti-inﬂammatory effect, resulting in beneﬁcial
metabolic outcomes, is substantial. In humans, the evidence of anti-
inﬂammatory effect is sparse, and substantial conﬂicting data exist.
About half of the studies ﬁnd amodest anti-inﬂammatory effect where-
as the other half are unable to detect any anti-inﬂammatory effect. The
disagreeing results might result from differences in study design, dose
regimens, study population etc. In order to clarify the role of resveratrol
in relation to anti-inﬂammatory potential in humans suffering from var-
ious conditions associated with low-grade inﬂammation, more large-
scale randomized studies with the anti-inﬂammatory effect as the pri-
mary outcome are urgently needed in well-characterized patient popu-
lations and using both high and low resveratrol dosage regime.
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